Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily
- Conditions
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT01814137
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT01773798
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
- Conditions
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 274
- Registration Number
- NCT01713530
- Locations
- 🇳🇴
Novo Nordisk Investigational Site, Stavanger, Norway
Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 753
- Registration Number
- NCT01707134
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom
Comparison of Two Insulin Aspart Formulations in Healthy Volunteers
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01698697
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Bloemfontein, South Africa
Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 131
- Registration Number
- NCT01697631
- Locations
- 🇵🇱
Novo Nordisk Investigational Site, Wroclaw, Poland
Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 131
- Registration Number
- NCT01697657
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Trelleborg, Sweden
A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 43
- Registration Number
- NCT01682902
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Atlanta, Georgia, United States
Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 64
- Registration Number
- NCT01678235
- Locations
- 🇵🇱
Department of Pediatrics, Medical University of Warsaw, Poland, Warsaw, Poland
Safety and Efficacy of Insulin Aspart in Type 2 Diabetes
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 123
- Registration Number
- NCT01649570
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.